featured
Gemcitabine + Cisplatin vs Fluorouracil + Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
J. Clin. Oncol 2021 Aug 11;[EPub Ahead of Print], S Hong, Y Zhang, G Yu, P Peng, J Peng, J Jia, X Wu, Y Huang, Y Yang, Q Lin, X Xi, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao, W Fang, L ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.